Literature DB >> 19523858

Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.

Nathan Lawrentschuk1, Fook T Lee, Gareth Jones, Angela Rigopoulos, Angela Mountain, Graeme O'Keefe, Anthony T Papenfuss, Damien M Bolton, Ian D Davis, Andrew M Scott.   

Abstract

OBJECTIVES: In tumors, hypoxia stimulates angiogenesis and correlates with treatment resistance and poor prognosis. We have previously demonstrated hypoxia in human renal cell carcinoma (RCC) via direct oxygen probe measurements. Carbonic anhydrase IX (CA IX) is a protein stimulated by hypoxia and involved in angiogenesis, and is a potential tumor target for imaging and therapies using cG250, a monoclonal antibody that recognizes CAIX. Our objectives were to characterize intratumoral hypoxia in a human RCC xenograft model using oxygen probe measurements; investigate if (124)I-cG250 targets RCC correlating uptake on noninvasive positron emission tomography-computerized tomography (PET-CT) against traditional biodistribution studies, and investigate CAIX expression in this RCC model.
METHODS: BALB/c nude mice had human RCC (SK-RC-52) subcutaneously xenografted with oxygen levels measured by probe. Positron emission tomography (PET/CT) and biodistribution studies ((124)I-cG250) were correlated with oxygen measurements. Immunohistochemistry and autoradiography were performed on selected tumors to confirm CAIX expression.
RESULTS: Oxygen tension in normal tissue (muscle) was 35.08 ± 2.41 mmHg (mean ± 95% CI), significantly greater compared to xenograft SK-RC-52 tumors at 5.02 ± 1.12 mmHg. Biodistribution studies of (124)I-cG250 demonstrated isotope uptake in SK-RC-52 xenografts peaking at 23.45 ± 5.07% ID/g (mean ± SD) 48 hours after antibody injection, which was maintained for a further 2 days (19.43 ± 4.31 and 10.64 ± 5.64 % ID/g, respectively). PET studies demonstrated excellent localization of (124)I-cG250 in tumor, and a significant correlation between SUVmean, SUVmax, and %/ID (124)I-cG250. CAIX expression was present in all groups studied but there was no significant correlation between it and any oxygen parameter studied.
CONCLUSION: Intratumoral hypoxia does exist within a human RCC xenograft model using invasive oxygen probe measurements. (124)I-cG250 targets RCC with correlation between uptake on noninvasive PET-CT studies and traditional biodistribution studies opening the possibility of using PET/CT in future studies. Finally, CAIX expression was not related to hypoxia in this model, supporting the hypothesis that cell lines may subvert known hypoxia mechanisms in hypoxic environments.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523858     DOI: 10.1016/j.urolonc.2009.03.028

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  18 in total

Review 1.  Functional imaging of renal cell carcinoma.

Authors:  Nathan Lawrentschuk; Ian D Davis; Damien M Bolton; Andrew M Scott
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Authors:  Peter J Houghton; Richard Lock; Hernan Carol; Christopher L Morton; Doris Phelps; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Amy W Wozniak; Yongchuan Gu; William R Wilson; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-12-27       Impact factor: 3.167

Review 3.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

Review 4.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 5.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

Review 6.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

7.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 8.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

9.  Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.

Authors:  Sean Carlin; Nahida Khan; Thomas Ku; Valerie A Longo; Steve M Larson; Peter M Smith-Jones
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

10.  ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.

Authors:  Alexander B Stillebroer; Gerben M Franssen; Peter F A Mulders; Wim J G Oyen; Guus A M S van Dongen; Peter Laverman; Egbert Oosterwijk; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2013-05-22       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.